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Abstract
Introduction: Elafin is an elastase-specific inhibitor with increased transcription in normal mammary epithelial cells
compared to mammary carcinoma cells. In this report, we test the hypothesis that inhibition of elastase, through
induction of elafin, leads to inhibition of human breast cancer cell viability and, therefore, predicts survival in breast
cancer patients.
Methods: Panels of normal and immortalized breast epithelial cells, along with breast carcinoma cells, were used
to examine the impact of adenoviral-mediated elafin expression or shRNA-mediated inhibition of elastase on the
growth of cells and xenografts in nude mice. To determine the prognostic significance of decreased elafin in
patients with invasive breast cancer, previously published gene array datasets were interrogated.
Results: Elafin expression had no effect on non-tumorigenic cells but resulted in marked inhibition of cell growth
in breast cancer cell lines. Control-treated xenografts generated a tumor burden that necessitated sacrifice within
one month of initial treatment, whereas xenograft-bearing mice treated with Ad-Elafin were alive at eight months
with marked reduction in tumor growth. Elastase inhibition mimicked these results, showing decreased tumor cell
growth in vitro and in vivo. Low expression of elafin gene correlated with significantly reduced time to relapse, and
when combined with high expression of elastase gene was associated with decreased survival in breast cancer
patients.
Conclusion: Our data suggest that elafin plays a direct role in the suppression of tumors through inhibition of
elastase and thus serves as a prognostic indicator for breast cancer patients.
Introduction
Polymorphonuclear leukocyte elastase (hereafter referred
to as elastase) disintegrates matrix proteins [1], implicat-
ing this enzyme in breast cancer cell invasion and
metastasis. Elastase is produced by neutrophils and also
by human breast cancer cells but not by normal breast
epithelial cells in culture [2]. Increased levels of elastase
have been shown to be strongly associated with recur-
rence and death in breast cancer patients [3]. A study of
313 breast cancer patients with a median of 18.5 years
of follow-up showed that elastase in tumor extracts was
an independent prognostic factor associated with
increased risk of recurrence [4]. These studies suggest
that elastase could have a role in tumor progression
leading to metastasis in breast cancer. The use of elas-
tase inhibitors to reverse the effects of elastase in acute
lung injury and to inhibit formation of atherosclerotic
plaques has been explored in experimental models [5,6].
A natural inhibitor of elastase, called elafin, was identi-
fied by subtractive hybridization comparing genes
expressed in normal human mammary epithelial and
human breast carcinomas [7]. Zani et al. showed that
elafin is a potent inhibitor of elastase activity in vitro
[8]. Adenoviral delivery of elafin was able to protect
endothelial cells from elastase-induced production of
cytotoxic products, which resulted in a decrease of
atherogenic stimuli and inhibition of elastase-induced
lung hemorrhage [5,6]. Lastly, in a mouse model of coli-
tis, elafin overexpression inhibited elastase-associated
inflammation [9]. These studies suggest that elafin inhi-
bits the function of elastase in vivo.
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A lack of elastase inhibition would provide a signifi-
cant advantage to cancer cells with respect to the meta-
static process. Elafin is expressed in well-differentiated
squamous cell carcinoma of the skin and esophagus but
is lost in poorly differentiated tumors [10-13]. Elafin was
found in tumor cell nests, and DNA fragmentation was
noted in these cell layers, suggesting that elafin was
involved in induction of apoptosis [13]. Elafin was found
in the cytoplasm just beneath the cell membrane, and
elastase was present adjacent to these elafin-positive
cells [11,12], suggesting that elafin is involved in sup-
pressing the progression of tumors, possibly through
inhibition of elastase.
However, it is unclear what the relationship between
elafin and elastase is in cells and whether elafin can
inhibit elastase mediated tumor progression. We investi-
gated the role of elafin expression and inhibition of elas-
tase in mediating tumor-specific growth inhibition in
breast cancer cells and the prognostic significance of
elafin in predicting outcomes in breast cancer patients.
Materials and methods
Microarray analysis
Gene expression and patient outcomes data were obtained
from previously published datasets [14,15]. Affymetrix
Human U133a Gene chips (Santa Clara, CA, USA) were
used to assess the expression of 22,000 transcripts in each
cohort. The Wang dataset was from analysis of total RNA
obtained from frozen tumor samples from 286 patients
with lymph node-negative breast cancer who had not
received systemic adjuvant therapy [15]. The expression
data for elafin (PI3) and elastase (ELA2/ELANE) genes and
the relationship between their expression and time to
relapse were analyzed using a log-rank test and shown
using Kaplan-Meier survival plots. The cutoffs for high
versus low expression were optimized to achieve the low-
est P-value. The ranges of expression using the PI3 probe-
s41469_at and 203691_at were 4.73 to 8.59 and 5.02 to
10.23, respectively, and the cutoffs were optimized at
5.042 and 5.44, respectively. The estrogen receptor (ER)
status was available for each tumor sample, and the elafin
levels were compared between the ER-positive and ER-
negative groups using the two-sample Student’s t-test.
Cell culture
Immortalized mammary epithelial cell lines 76NE6,
76NF2V, 76NY54H, 76NE7 and MCF-10A were gifts of
Dr. Vimla Band (University of Nebraska Medical Center,
Omaha, NE, USA) [16-18]. 76NE6 and 76NE7 were
immortalized through transfection of normal mammary
epithelial cells (76N) with the E6 and E7 genes of the HPV
genome, rendering them p53 or pRb defective, respectively.
76NF2V and 76NY54H cells were also immortalized with
the E6 gene. However, point mutations were introduced
into the E6 gene so that these cells maintain functional p53
while being immortalized. MCF-10A cells were immorta-
lized through long-term culture in serum free media. ER-
positive breast carcinoma cell lines (MCF-7, ZR75T and
BT20T), ER-negative breast carcinoma cell lines (T47D,
HBL100, MDA-MB-436, MDA-MB-231 and MDA-MB-
157) and NIH3T3 fibroblasts were obtained from the
American Type Culture Collection (Manassas, VA, USA).
Cells were cultured in medium from HyClone (Logan, UT,
USA) containing serum obtained from Atlanta Biologicals,
Inc. (Lawrenceville, GA, USA). The cells were cultured at
37°C in 6.5% CO2. All cells were authenticated by cytoge-
netic testing at the Characterized Cell Line Core Facility at
MD Anderson Cancer Center and were verified as being
free of mycoplasma contamination by PCR.
Adenoviral vectors
Recombinant adenoviral vectors Ad-Luc and Ad-Elafin
were constructed by inserting the cytomegalovirus pro-
moter plus the transgene (luciferase or elafin) into the
E1 region of an E1/E3-deleted type 5-adenovirus as
described previously [9,19,20]. Virus titers were deter-
mined by measuring optical absorbance at A260 and by
plaque-forming assays. Particle to plaque ratios fell
between 10:1 and 100:1. All of the viral preparations
were free of E1A contamination and endotoxins. Trans-
duction efficiency was previously determined using an
adenoviral vector containing the b-galactosidase reporter
gene under control of the cytomegalovirus promoter. In
previous reports, we showed that at a multiplicity of
infection of 2,000 viral particles (vp), 85% to 95% of the
cells were infected, and the recombinant adenoviruses
induced high levels of transgene expression [21].
Western blot analysis
Total cell extracts were prepared with cell lysate buffer,
and cell extracts were analyzed for protein content by
SDS-PAGE as described previously [21]. Briefly, 50 μg of
protein was subjected to electrophoresis on a 10% or 13%
SDS-PAGE gel. Protein was then transferred to Immobi-
lon P membranes (Millipore, Billerica, MA, USA), which
were blocked overnight in BLOTTO (5% nonfat dried
milk in 20 mM Tris, 137 mM NaCl and 0.05% Tween (pH
7.6)). After washing, the blots were incubated in primary
antibodies for 2.5 h. Primary antibodies used were elafin
(HM2063; HyCult Biotech, Uden The Netherlands) and
actin (Chemicon International, Inc., Temecula, CA, USA).
Blots were then incubated with horseradish peroxidase
conjugated secondary antibodies at a 3:5,000 dilution
in BLOTTO for 1 h, washed, and developed by chemilu-
minescence (Western Lightning Chemiluminescence
Reagent Plus; Perkin-Elmer Life Sciences, Cambridge, UK)
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according to the manufacturer’s instructions. Actin was
used to standardize equal loading. Uncropped blots are
shown in Additional file 1.
Confocal microscopy
Cells (4 × 105) were grown on poly-L-lysine-coated cover-
slips (Corning Biosciences, Lowell, MA, USA) in six-well
plates for 12 h. Cells were fixed with 2% paraformaldehyde
and incubated for 15 minutes with 70% ethanol, washed
and covered with 1% gelatin. Cells were rinsed with PBS,
permeabilized with 0.2% Triton X-100, blocked with 1%
goat serum (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA; sc-2043) and then incubated with antibody to
either elafin (Santa Cruz Biotechnology; sc-20637) or elas-
tase (Merck KGaA, Darmstadt, Germany; 481001) diluted
1:200 in 3% bovine serum albumin in a humidified box
overnight at 4°C. Detection was performed with anti-rabbit
Rhodamine Red-X-conjugated secondary antibodies (Invi-
trogen, Carlsbad, CA, USA; R6394; 1:400 dilution), or
Alexa Fluor 555 or Alexa Fluor 488 goat anti-mouse anti-
bodies (Invitrogen; A21428 and A11008 respectively; 1:300
dilution). For elastase shRNA experiments, two secondary
antibodies were used to confirm knocked down expression
as no antibody is available for Western blotting. Cells were
rinsed, followed by the addition of one drop of mounting
medium (Invitrogen; P36935) and 4’,6-diamidino-2-pheny-
lindole (DAPI). Imaging was performed on an Olympus
FV500 confocal microscope (Olympus America Corporate
Headquarters, Center Valley, PA, USA).
Proliferation and invasion assays
For proliferation analyses, cells were seeded at 5 × 103
cells per well in 24-well plates, and cells were infected
with Ad-Elafin (2,000 vp/mL and 2,500 vp/mL) or with
Ad-Luc (2,000 vp/mL and 2,500 vp/mL) or mock-
infected with PBS and evaluated by direct cell counting
by hemocytometer of duplicate plates at Days 1, 2, 3 and
4. Invasion assays were carried out using Oris Cell Migra-
tion Assay Kit according to the manufacturer’s instruc-
tions (Platypus Technologies, Madison, WI, USA). A
total of 1 × 105 cells were seeded around stoppers that
created a detection zone, and incubated overnight. The
stoppers were removed from test wells but left in place in
the pre-migration reference wells until assay readout. All
wells received CellTracker Green (Platypus Technolo-
gies) to fluorescently stain the cells. Cell migration was
measured by fluorescence signals in the detection zones
using a plate reader. Fluorescence was monitored at exci-
tation and emission wavelengths of 492 nm and 530 nm,
respectively. Images of pre-migration wells (time = 0 h)
and post-migration wells (time = 48 h) were acquired
using fluorescence microscopy with an Olympus FV500
confocal microscope.
shRNA-mediated down-regulation of elastase and elafin
shRNA vectors against elastase (TG310440) and a control
vector containing a scrambled transcript (TR30012) were
obtained from Origene (Rockville, MD, USA). Cells were
transfected with 5 μg of vector using Genejuice reagent
(Novagen, Madison, WI, USA) according to the manufac-
turer’s instructions. Cells expressing these vectors were
selected in a-minimal essential medium containing 2 μg/
mL puromycin (Sigma, St. Louis, MO, USA) for four
weeks. Single-cell clones were selected and expanded in
culture medium supplemented with 0.1 mg/mL G418 and
2 μg/mL puromycin (Sigma) and screened by Western
blot. Elastase activity was measured using MeOSuc-
Ala-Ala-Pro-Val-pNA (Sigma-Aldrich) as a substrate.
Lysates from 76NE6 cells with or without knock-down of
elafin were incubated with 350 μg of 2 mM substrate for
48 hours in reaction buffer (0.1 M Tris 7.5, 0.5 M NaCl)
and absorbance was measured at 405 nM.
Mouse xenograft studies
Mice were housed five per cage in sterilized micro-isolator
cages (Lab Products, Seaford, DE, USA) furnished with
corncob bedding. Mice received care in accordance with
the Animal Welfare Act, the National Institutes of Health
“Guide for the Care and Use of Laboratory Animals” and
the institutional guidelines of MD Anderson Cancer
Center. All experiments were approved by the Institutional
Animal Care and Use Committee at MD Anderson Cancer
Center. A total of 1 × 106 cells were injected into the
mammary fat pad of four- to six-week-old female Balb/c
Nu/nu mice (Taconic, Germantown, NY, USA). For treat-
ment with elafin, MDA-MB-468 breast cancer cells were
xenografted. When the tumor size reached 100 mm3, mice
were divided into treatment groups. The tumors were
treated with 2 × 1010 vp/mL Ad-Elafin (n = 6), 2 × 1010
vp/mL Ad-Luc (n = 4), or PBS (n = 4) on Days 1, 5, 8 and
12. To observe effects of elastase shRNA on tumor growth,
nude mice were injected with MDA-MB-231 breast cancer
cells treated with a combination of either the two control
vectors (n = 8) or the two elastase shRNA constructs (n =
8) in the mammary fat pads. The tumor volume was calcu-
lated every other day. Mice were euthanized when tumors
were greater than 1.5 cm in diameter at the widest dimen-
sion of the tumor.
Immunohistochemical analysis
Hematoxylin and eosin staining was performed on sec-
tions cut from tumor tissue embedded in paraffin blocks.
The sections were stained with polyclonal antibodies to
either elafin (Santa Cruz Biotechnology; sc-20637) or
elastase (Calbiochem, Billerica, MA, USA; 481001)
diluted 1:200 in 3% bovine serum albumin. Protein
expression was visualized with avidin-biotin-peroxidase
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reagent using a Vectastain ABC kit (Vector Laboratories,
Burlingame, CA, USA) according to the manufacturer’s
recommendations.
Results
Elastase inhibition decreases proliferation of breast
cancer cells
Higher amounts of neutrophil elastase in breast cancer
tissues from patients are associated with a poor prog-
nosis [4,22]. To determine the effects of silencing elas-
tase in breast cancer cells, MDA-MB-231 cells were
treated with shRNA against elastase. Two cell clones
were selected that had been treated with shRNA specific
to elastase (231-Elastase1 and 231-Elastase2), or with
nonspecific shRNA constructs as controls (231-Control1
and 231-Control2). Using confocal microscopy, strong
expression of elastase was observed in MDA-MB-231
cells without shRNA treatment and in the control clones
(Figure 1A). However, the clones treated with shRNA
against elastase had reduced elastase expression (Figure
1A). qRT-PCR was performed on the clones to confirm
and quantify the extent of down-regulation of elastase
expression after shRNA treatment and showed that
expression was significantly reduced compared to the
231-Control1 cells (Figure 1B).
In response to the down-regulation of elastase, MDA-
MB-231 cells had only a moderate reduction in prolifera-
tion compared to the control clones. For example, by
Day 5 of a growth curve, the 231-Elastase1 clone showed
only a 50% reduction in cell number compared to the
231-Control1 clone (Figure 1C, D). To gauge whether the
modest reduction in proliferation induced by knocking
down elastase could decrease cell colony formation, clo-
nogenic assays were performed. Decreased elastase
expression resulted in a significantly reduced ability of
MDA-MB-231 cells to form colonies compared to
untreated or control-shRNA-treated MDA-MB-231 cells
(Figure 1E, F).
Elastase inhibition inhibits matrix invasion by breast
cancer cells
Elastase is known to be secreted by cancer cells to invade
extracellular matrix and facilitate cell migration [23]. To
determine whether invasion of breast cancer cells could be
abrogated by depletion of elastase, we performed an inva-
sion assay to measure the ability of breast cancer cells to
invade a collagen matrix. Results revealed that following
elastase down-regulation, MDA-MB-231 could no longer
invade the collagen field compared to the control cells.
Specifically, in the clones with elastase knocked down, the
invading cells consumed only 41% of the collagen matrix
field, compared to 82% consumed by the control cells
(Figure 2A, B). A scratch assay was also performed on the
same cell lines to corroborate these data. After 12 hours,
77% and 89% of the scratch made in the cells with reduced
elafin remained compared to 49% and 57% in the control
cells (Figure 2C, D). Collectively, these data suggest that
inhibition of elastase in breast cancer cells limits their
invasive and migratory properties.
Elastase facilitates tumor progression in mice
Our data, thus far, suggest that elastase affects both the
proliferation and invasion of cancer cells. Therefore, we
hypothesized that suppression of elastase would signifi-
cantly decrease tumor burden in a xenograft model. To
test this hypothesis, we injected MDA-MB-231cells
transfected with control or elastase shRNA into the
mammary fat pads of nude mice to form xenografts.
The mice were assessed for tumor formation and tumor
size daily for a month. The mice injected with breast
cancer cells transfected with control shRNA developed
tumors that necessitated sacrifice by 31 days; however,
the mice injected with breast cancer cells transfected
with elastase shRNA had minimal, mostly nonpalpable
tumors for the duration (that is, 30 days) of the study
(Figure 2E, F). These data suggested that elastase inhibi-
tion is sufficient for inhibition of tumor progression.
Elastase and elafin have an inverse pattern of expression
Our data (Figure 2E, F) suggest that elastase inhibition
could delay breast cancer progression. However, to date,
there are no clinically available small molecule inhibitors
of neutrophil elastase. We hypothesized that elafin, an
endogenous inhibitor of elastase, inhibits elastase and
that cells expressing elafin would be phenotypically
similar to cells described above that lacked elastase. We
initially evaluated the cellular location and level of
expression of elafin and elastase in non-tumorigenic and
breast carcinoma cells using confocal immunofluores-
cence microscopy to determine if these molecules are
co-localized inside the cell (Figure 3A). The non-tumori-
genic mammary epithelial cells (Figure 3A, top panel)
demonstrated high levels of elafin expression within the
nucleus and lower levels of elafin expression within the
cytoplasm. All of these cells, except 76N, demonstrated
low but detectable levels of elastase expression within
the nucleus, suggesting an inverse relationship between
the two proteins. In contrast, the breast carcinoma cell
lines (Figure 3A, middle and bottom panels) showed
overall low levels of elafin expression and high levels of
elastase expression within both the nucleus and the
cytoplasm. Quantification confirmed that non-tumori-
genic mammary epithelial cells had high elafin expres-
sion and low elastase expression and that breast
carcinoma cells had low or no elafin expression and
high elastase expression (Figure 3B). These data showed
that elafin, when present, may inhibit elastase seeing
that elastase levels are increased in the absence of elafin.
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To confirm a direct and inverse relationship between ela-
fin and elastase, 76NE6 cells, which are non-tumorigenic
and have high levels of elafin, were treated with shRNA
constructs against elafin to generate two clones (Elafin 1
and Elafin 2) of cells that lacked elafin expression (Figure
3C). Decreased elafin expression in this non-tumorigenic
cell line led to a significant increase in elastase activity com-
pared to the empty vector controls suggesting a cause and
effect relationship between elafin and elastase (Figure 3D).
Adenoviral-mediated elafin expression results in growth
delay in breast cancer cells
Elafin expression differs at the level of transcription
between normal mammary epithelial cells and breast car-
cinoma cells [7,24]. Our data (Figure 3) suggested that
tumor cells lack expression of the elafin protein and that
a decrease in elafin is associated with increased elastase
expression and activity. To further investigate whether
the differences between normal and tumor cells persist
after translation, we evaluated elafin protein expression
in mammary epithelial and breast carcinoma cells. Elafin
protein was expressed in all of the non-tumorigenic
breast epithelial cells, mortal or immortal (Figure 4A). In
contrast, elafin protein was not expressed in any of the
breast carcinoma cell lines, whether positive for ER or
not (Figure 4A), suggesting that elafin is differentially
expressed at the protein level between normal and tumor
cells.
The dynamic relationship between elafin and elastase
and the observation that elafin is mainly expressed in
Figure 1 shRNA-mediated downregulation of elastase decreases proliferation of MDA-MB-231 cells. MDA-MB-231 cells were selected that
stably expressed control, scrambled shRNA (231-Control1 and 231-Control2) or elastase-specific shRNA (231-Elastase1 and 231-Elastase2). A)
Down-regulation of elastase was confirmed by confocal microscopy of each clone and the parental cells using Alexa Fluor 555 (red) and Alexa
Fluor 488 (green) goat anti-rabbit secondary antibodies against an elastase primary antibody along with DAPI nuclear stain. B) qRT-PCR was
performed on RNA from the control and elastase shRNA treated cells. A Student’s t-test was used to determine the significance of the down-
regulation (**P < 0.01). C and D) Cells of each clone were counted every day for five days. Three independent growth curves were generated in
this manner and the average of each cell count was graphed. Error bars indicate standard error and differences between parental and elastase
shRNA cells were detected using a Student’s t-test (*P < 0.05, ***P < 0.001). E and F) Cells of each clone were subjected to clonogenic assays,
the resulting clones were enumerated and subjected to Student’s t-test (**P < 0.01, ***P < 0.001).
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normal cells and not detectable in tumor cells (Figure 4A)
led us to hypothesize that breast cancer cells expressing
elafin have decreased tumorigenic potential, similar to that
observed in breast cancer cells with elastase inhibited by
shRNA (Figures 1, 2, 3). To test this hypothesis, we evalu-
ated the impact of elafin expression on cell growth and
viability. The 76NE6 cells with high endogenous elafin
expression (Figure 4A), and four breast carcinoma cell
lines with low elafin expression were infected with a
recombinant adenovirus containing the luciferase reporter
gene (Ad-Luc) or the elafin transgene (Ad-Elafin). The
76NE6 cells had markedly increased elafin expression after
infection with Ad-Elafin (Figure 4B). The breast carcinoma
cell lines, which had low endogenous elafin expression
(Figure 4A) upon infection with Ad-Elafin, expressed ela-
fin at similar levels to what is detected at baseline in the
normal mammary epithelial cells (Figure 4B).
As shown in Figure 4C, in the non-tumorigenic mam-
mary epithelial cells (76NE6 and MCF-10A), there was no
demonstrable decrease in cell growth following treatment
Figure 2 Elastase inhibition reduces tumor cell invasion and growth of xenografts. A) MDA-MB-231 cells stably expressing control,
scrambled shRNA (231-Control1 and 231-Control2) or elastase-specific shRNA (231-Elastase1 and 231-Elastase2) were assessed for invasion of a
collagen matrix at baseline and after 48 h. B) The percentage of the collagen matrix field that was invaded by each clone was quantified for
triplicate wells and the mean was graphed. Significance was measured using a Student’s t-test (*P < 0.01). C) Cells were also subjected to a
scratch assay to detect the percentage of a scratched field that would be replaced by migrating cells within 12 hours. D) Three different
replicates of scratch assay were performed and the average was calculated along with the standard error (shown as bars) and the P-value was
calculated using a Student’s t-test (*P < 0.05 compared to 231- Control 2,**P < 0.01 compared to both control clones). E and F) Cells transfected
with nonspecific shRNA (control) or elastase-specific shRNA were injected into the mammary fat pad of mice, and tumor formation was
observed and measured for five weeks. The results show the average of two replicate experiments.
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with PBS, Ad-Luc or Ad-Elafin, despite the high levels of
elafin overexpression achieved (Figure 4B). In contrast, in
each of the breast carcinoma cell lines expressing elafin
(via Ad-elafin) at the physiological levels of what is found
in normal cells, there was a reduction in cell number over
time (Figure 4C). As expected, there was no substantial
difference in cell growth between breast carcinoma cells
treated with Ad-Luc and those treated with PBS, showing
that the inhibition was attributable to the presence of
elafin. There was significant apoptotic cell death in the
Ad-Elafin-treated breast carcinoma cells compared to the
Ad-Luc-treated breast carcinoma cells (P < .001; Addi-
tional file 2). Therefore, elafin expression negatively
regulates the proliferation of breast cancer cells in part
through induction of apoptosis.
Elafin treatment results in growth delay of established
xenografts
Elastase inhibition by shRNA provides a means to
decrease the tumor burden in a xenograft model (Figure
2C, D). To further assess if overexpression of elafin and
down-regulation of elastase have similar physiological end-
points, we next investigated the effect of elafin expression
on tumor progression in an in vivo model. MDA-MB-468
cells were injected into the mammary fat pad of nude
mice and were then treated with Ad-Luc, PBS or Ad-Elafin
Figure 3 Elafin and elastase have an inverse pattern of localization. A) Non-tumorigenic breast epithelial cell lines (top panel), ER-positive
breast cancer cell lines (middle panel) and ER-negative breast cancer cell lines (bottom panel) were subjected to confocal microscopy to detect
the levels of elafin and elastase expression (red) and their localization in the cytoplasm and nucleus (blue). B) The number of cells expressing
elafin and elastase for each cell line was quantified. C) Western blots confirm down-regulation of elafin by shRNA constructs, Elafin 1 (lane 3)
and Elafin 2 (lane 4), compared to parental and empty vector control cells (lanes 1 and 2, respectively). D) Elastase activity was determined by
measuring the amount of substrate cleaved by elastase and was detected by spectrophotometry in 76NE6 and 76NF2V clones with either an
empty vector or shRNA against elafin, Elafin 1 and Elafin 2 (*P < 0.05,**P < 0.001).
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Figure 4 Elafin is expressed in non-tumorigenic mammary epithelial cells but not breast cancer cells. A) Lysates were collected from a
panel of non-tumorigenic breast epithelial cells (mortal and immortal) and breast cancer cells (ER-positive and ER-negative) and subjected to
Western blot analysis to detect elafin expression. B) Elafin levels were also assessed after treatment with PBS, Adenoviral luciferase (Luc), or elafin.
Actin expression was assessed as a loading control. C) Breast cancer cell lines (MDA-MB-436, MDA-MB-157, MDA-MB-231 and MDA-MB-468) and
non-tumorigenic breast epithelial cells (76NE6 and MCF-10A) were treated with PBS, luciferase (Luc) or elafin, cultured and counted for each day
for four days.
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and the tumor burden was monitored over the duration of
the study. Tumors in the mice treated with Ad-Luc or PBS
continued to grow, requiring sacrifice within 45 days. How-
ever, there was an immediate cessation in tumor growth in
the mice treated with Ad-Elafin (P < .0001, Figure 5A). All
of the mice treated with Ad-Elafin remained alive for at
least 45 days after initial treatment (Figure 5B). Ten of the
12 mice treated with Ad-Elafin experienced tumor growth
necessitating sacrifice between Days 50 and 100. At eight
months after initial treatment, one mouse treated with
Ad-Elafin had experienced a decrease in tumor size to less
than 30 mm3, and one had experienced complete resolu-
tion of the tumor. Elafin treatment resulted in significantly
improved event-free survival compared with PBS or
Ad-Luc treatment (P < 0.001, Figure 5B).
Elafin loss is associated with ER-positive, poor-prognosis
breast cancer and shorter time to relapse
We next asked if changes in expression of elafin or elas-
tase in breast tumors are correlated with changes in
patient outcome. To this end, we assessed elafin gene
(PI3) expression in previously published microarray data
from node-negative breast cancer patients [15]. On the
basis of expression of PI3, as detected by two probes, the
patients in the cohort were stratified as having high or low
expression. High PI3 expression was associated with
a longer time to relapse (P = .027) (Figure 6A, B). By
48 months, 63% of patients with low levels of elafin had
had a relapse. In contrast, by 80 months, 64% of patients
with high levels of elafin remained free of disease. Addition-
ally, lower levels of elafin expression were associated with
ER-positive tumors (P = .00015, Figure 6C, D). These data
suggest that loss of elafin correlates with a subset of breast
cancers and may contribute to their distinct phenotype.
Overall, the data from the Wang et al. cohort suggested
that low elafin expression is an indicator of poor prognosis
in patients with lymph node-negative breast cancer.
Analysis of a second microarray dataset [25] supported
these findings and showed that patients with the combi-
nation of high levels of elastase (ELA2) expression conco-
mitant with low levels of elafin expression were more
likely to relapse and die from their breast cancer sooner
after diagnosis than patients with high elafin expression
and low elastase expression (P = .05, Figure 6E). After
eight months, the proportion of patients alive was more
than 20% higher in the elafin-high, elastase-low group.
These data showed that elafin and elastase have an
inverse relationship and that increased elastase expres-
sion and decreased elafin expression correlate with a
poor prognosis in breast cancer patients.
Discussion
In this report, we show an inverse relationship between
elastase and elafin protein expression and physiological
functions in cell lines, in mice and in patients. In non-
tumorigenic cell lines, elafin was detected, but elastase
levels were low. In tumor cell lines, the reverse relation-
ship was observed. To determine how an imbalance of
elastase and elafin in tumor cells could increase their
tumorigenic potential, we overexpressed elafin or
knocked down elastase in tumor cells. We found that
the presence of elafin or absence of elastase had very
similar physiological consequences, resulting in the inhi-
bition of proliferation and colony formation of the
tumor cells. In addition, increased elafin or decreased
elastase expression in mice resulted in decreased tumor
size and increased their survival. Lastly, in an analysis of
microarray data from breast cancer patients, the combi-
nation of high levels of elafin and low levels of elastase
was associated with longer time to relapse. These results
suggest a very tight cross talk between elafin and elas-
tase across all model systems examined.
It is reasonable to infer from our findings that a
downward shift in elafin or an upward shift in elastase
could provide a tumor with the environment needed to
grow and progress. The pathways that this machinery
activates are likely both proliferation and invasion as
both pathways were shown to be decreased with down-
regulation of elastase. Elastase has been implicated in
cleaving several substrates that play direct roles in med-
iating these tumor-promoting pathways. For example,
elastase has been implicated in the cleavage of cyclin E
into its low-molecular-weight forms, which are capable
of deregulating the cell cycle [26-28], and this cleavage
is inhibited by elafin (data not shown). We have shown
in this work (Figure 6B) that exogenous elafin expres-
sion in tumor cells induces apoptosis to result in tumor
suppression. This confirms previous data showing elafin
dose dependent mediated apoptosis in breast cancer
cells that lacked pRb, but had a functional caspase-3
[29]. Others have shown that elafin mediates apoptosis
through a p53-dependent pathway in melanoma cells
[30]. Elafin has also been shown to induce apoptosis by
inhibiting elastase-mediated cleavage of CD14 [31]. Elas-
tase is implicated in the cleavage of cut homeobox 1
which accelerates S-phase entry and is inversely corre-
lated with survival [32-34]. Further research will be
needed to elucidate the pathways regulated by the elas-
tase/elafin switch.
Gene array data have previously been used to identify
gene signatures associated with breast cancer subtypes
and are invaluable tools for identifying genes associated
with disease outcome. We mined published datasets to
analyze the elafin gene expression in relation to time to
relapse. The combination of high elafin and low elastase
was associated with longer time to relapse. Because ela-
fin is regulated at the level of transcription, it will be
necessary to analyze elafin expression at the protein
Hunt et al. Breast Cancer Research 2013, 15:R3
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level to further investigate its role in the various breast can-
cer subtypes. The signal for elastase gene expression was
relatively low, which supports previous reports that neutro-
phils are a source of elastase and that it is taken up in an
active form by the cancer cells via endocytosis [35,36].
Manipulating the reciprocal relationship between elas-
tase and elafin to increase elafin expression could prove
beneficial to breast cancer patients. In combination with
targeted treatments or chemotherapy, inhibition of elastase
would inhibit tumor promoting activity in both the tumor
Figure 5 Elafin treatment of mice with breast cancer xenografts leads to increased survival. Nude mice with established MDA-MB-468
xenografts were treated with Ad-Elafin (n = 6), PBS (n = 4) or Ad-Luc (n = 4). A) Tumor volume was measured and recorded every other day.
Mice were sacrificed when tumors were greater than 1.5 cm in diameter, and B) survival was recorded. The results show the average of two
replicate experiments.
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cell and tumor environment. The efficacy of treatment
strategies designed to increase elafin expression could be
predicted by the presence of elastase substrates, such as
low-molecular-weight cyclin E. Because elafin is an endo-
genously expressed human protein, it could serve as the
ideal candidate for inhibiting elastase. Furthermore, these
data provide a rationale for testing elafin as a prognostic
marker in a prospective study.
Conclusions
In this study we show that elafin and elastase have a reci-
procal, but co-localized pattern of expression. Normal
Figure 6 Lower expression of the elafin gene (PI3) indicates a poor prognosis. PI3 expression evaluated using two separate probes (A and
C use 41469_at; B and D use 203691_at) was extracted from previously published datasets and correlated with A and B) time to relapse along
with C and D) ER expression by using a Kaplan Mier survival analysis. E) Expression of the ELA2 gene (which encodes for elastase) in
combination with the PI3 gene was also correlated with disease-specific survival.
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cells express higher amounts of elafin and low levels of
elastase expression whereas tumor cells have higher elas-
tase expression and minimal levels of elafin. Overexpres-
sion of elafin reduced proliferation of tumor, but not
normal, cell lines and growth of tumor cell xenografts.
Additionally, silencing elafin increased elastase activity.
Because of the role elafin plays in inhibiting elastase and
reducing breast cancer cell proliferation, we hypothesized
that it could be used as a prognostic marker in breast
cancer patients. Using microarray data, we showed the
low elafin expression is correlated with poor outcome.
Therefore, expression of elafin is an ideal candidate for a
therapeutic inhibition of elastase mediated breast cancer
progression and as a prognostic marker for breast cancer.
Additional material
Additional file 1: Uncropped Western blots. Western blots for actin
and elafin are shown before they were cropped for Figures 3 and 4.
Additional file 2: Ad-Elafin induces apoptosis in breast cancer cells,
but not normal cells. To determine whether apoptosis contributed to
the decreased cell proliferation and colony formation observed in the
Ad-Elafin-treated breast carcinoma cells, breast cancer cells (MDA-MB-
436) and non-tumorigenic mammary epithelial cells (76NE6) were
transfected with Ad-Luc, transfected with Ad-Elafin, or treated with PBS
and stained with propidium iodide, and the apoptotic fraction was
determined by flow cytometry. There was significant apoptotic cell death
in the Ad-Elafin-treated breast carcinoma cells compared to the Ad-Luc-
treated breast carcinoma cells (P < .001). There was no significant
apoptosis noted in the normal mammary epithelial cells treated with Ad-
Elafin, demonstrating that elafin induces apoptosis in cancer cells,
causing tumor-specific growth inhibition. These data showed that elafin
expression negatively regulates the proliferation of breast cancer cells at
least partially through induction of apoptosis. Analysis of apoptosis was
performed with propidium iodide staining. All cells (floating and
adherent) were centrifuged at 2,000 rpm for five minutes at 4°C. The cell
pellets were then washed once with PBS and resuspended with 1 μl of
propidium iodide per sample. The sub-G1 fraction was analyzed using a
FACS Calibur flow cytometer (BD Biosciences, San Jose, CA, USA).
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